- CH₣232.94bn
- CH₣265.12bn
- $56.33bn
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'
Brief: Novartis Delpacibart Braxlosiran Phase I/II Study In Facioscapulohumeral Muscular Dystrophy Meets Primary Biomarker Endpoint
Analysis: Businesses fear for economy if Swiss vote to cap population at 10 million
Swiss firms invest $27 billion in US after tariff deal, NZZ am Sonntag reports
Celcuity rises after boosted $500 mln convertible bond offering
Swiss stocks - Factors to watch on June 4
Brief: Novartis Cosentyx® Pmr Data In New England Journal Of Medicine Showed Sustained Remission Versus Placebo In Twice As Many Patients
Celcuity drops further after announcing $400 mln convertible offering
Celcuity plunges after experimental breast cancer treatment data disappoints
Table: Swiss trade surplus at CHF 3.098 bln in April
Swiss stocks - Factors to watch on June 1
Experimental Novartis radiopharma drug shows promise in early study
Brief: Novartis' Pluvicto™ Demonstrated Consistent Efficacy Across Key Patient Subgroups In Metastatic Hormone-Sensitive Prostate Cancer
China's commerce ministry holds meeting with foreign pharmaceutical firms
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
Brief: Novartis: Pluvicto Psmaddition Data To Highlight Efficacy In Metastatic Hormone-Sensitive Prostate Cancer